ClinicaliQ Trial Snapshot
- A Masked, Placebo-controlled Study to Assess Iptacopan in Age-related Macular Degeneration — Active Not Recruiting • Phase II • NCT05230537.
- Iptacopan tested to prevent progression of early-to-intermediate age-related macular degeneration to advanced vision loss.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The purpose of this study is to assess the effect of Iptacopan to prevent conversion of early or intermediate age-related macular degeneration (AMD) eyes to new incomplete retinal pigment epithelium and outer retinal atrophy (iRORA) or late AMD. Conditions: Age-Related Macular Degeneration Interventions: Iptacopan (LNP023), Placebo Lead Sponsor: Novartis Pharmaceuticals Planned Enrollment: 168 participants